Functional Genomics and Target Discovery
At oNKo-innate, we believe it’s important to understand the entire cancer-immunity cycle to advance novel cancer immunotherapies. With this in mind, we have developed a universal functional genomics approach for immuno-oncology that overcomes common issues in immuno-oncology screening.
in vitro screening of primary human immune cells
Our versatile CRISPR screening platform enables high-throughput phenotypic screening in hard-to-manipulate primary human immune cells. Our in-house immunology expertise allows us to select meaningful screening pressures and phenotypic readouts, and an integrated computational pipeline helps us identify and prioritise targets for further validation studies.
in vivo screening
As an orthogonal validation tool, and to access biological mechanisms that cannot be recreated in vitro, we have developed a sophisticated in vivo functional genomics platform. This platform can be applied to genetically manipulate all immune cell lineages, directly within the tumor microenvironment (TME). This unbiased and comprehensive approach allows us to identify novel genetic factors that can enhance anti-tumor immunity in the complex milieu of inflammatory and immunosuppressive signals typically found within the TME.
To accelerate the drug discovery process for our partners, we adapted our platform to screen novel compound libraries in a panel of bespoke, high throughput screening assays in primary immune cells. Powered by insights gleaned from our genetic screens about the most relevant functional readouts, our immsigHTS platform generates a detailed phenotypic fingerprint of the immunological effects of these compounds. Analysis of the resulting feature-rich, high-dimensional data allows us to identify the most promising compounds and the mechanisms that drive robust phenotypic changes in immune cells, including increased anti-tumor function.
Our functional genomics and screening platform and knowledge of immune cell biology drive target discovery, seeding the oNKo-innate development pipeline. Our unique in-house immunobiology screening capabilities also enable our partners to accelerate their own campaigns.
Here at oNKo, we’re combining our inimitable biological expertise with cutting-edge technologies to drive the immuno-oncology revolution.